Summary of findings 2. Topotecon compared to PLD for EOC.
| Topotecon compared to PLD for EOC | ||||||
| Patient or population: patients with EOC Settings: Intervention: Topotecon Comparison: PLD | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| PLD | Topotecon | |||||
| Survival Hazard Ratio (platium‐sensitive) Follow‐up: mean 3 years | See comment | See comment | 220 (1 study) | ⊕⊕⊕⊝ moderate1 | ||
| Survival Hazard Ratio (Platium‐resistant) Follow‐up: 3 years | Study population | RR 0.69 (0.35 to 1.38) | 255 (1 study) | ⊕⊕⊝⊝ low1,2 | ||
| 138 per 1000 | 96 per 1000 (48 to 191) | |||||
| Moderate | ||||||
| Progression free survival (platium‐sensitive) Follow‐up: median 5 years | See comment | See comment | 220 (1 study) | ⊕⊕⊕⊝ moderate1 | ||
| Progression free survival (platium‐resistant) Follow‐up: median 5 years | See comment | See comment | 220 (1 study) | ⊕⊕⊕⊝ moderate1 | ||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Lack of description about the randomisation method, allocation method and blinding. 2 The confidence interval is rather wide.